Avalo Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire•02/11/2026•16:00 ET
0
Key Highlights
- ➤Avalo management to join Guggenheim Healthcare Innovation Conference on November 9, 2026
- ➤Avalo management to join Stifel 2026 Healthcare Conference on November 10, 2026
- ➤Abdakibart advances toward a phase 3 registrational program in hidradenitis suppurativa
- ➤Avalo is developing AVTX-010, a long-acting next-generation anti-IL-1β mAb
WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:
Guggenheim Healthcare Innovation Conference Fireside Chat November 9, 2026 at 8:30am ET
Get started
Create a free account to read the full story.